Cargando...

Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation

ESSENTIALS: Factor VIII inhibitors are the most serious complication in patients with hemophilia A. Aggregates in biopharmaceutical products are an immunogenic risk factor. Aggregates were identified in recombinant full‐length factor VIII products. Aggregates in recombinant factor VIII products are...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Thromb Haemost
Autores principales: Healey, J. F., Parker, E. T., Lollar, P.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5809250/
https://ncbi.nlm.nih.gov/pubmed/29197156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.13917
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!